About

About Perseo pharma AG Gut Restricted Metabolic Therapies Perseo Pharma is a biopharmaceutical company pioneering innovative metabolic therapies. Founded in 2019 in Europe's leading Life Science hub, Perseo has assembled a world-class team and state-of-the-art facilities. The company has raised CHF 10 million from private investors, including a U.S. patient advocacy organization and a corporate fund. Perseo's proprietary platform technology enables the development of highly effective gut-restricted treatments for a range of metabolic disorders. The company is targeting conditions like Exocrine Pancreatic Insufficiency (EPI) and a family of rare diseases made of Intoxication-Type Inborn Errors of Metabolism, including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Congenital Sucrase-Isomaltase Deficiency (CSID), and Tyrosinemia. Each of these represents a market worth over $1 billion, and the compounds we are developing for these indications are eligible to Orphan Drug Designation (ODD). PER301, Perseo's lead compound for EPI (well established $1.5bn market in the US alone), is being developed in partnership with Nestlé Health Science. A significant commercial milestone for this collaboration is anticipated within 6-9 months. With a second partnership in place with another biotech company for IBD, an excellent partnering track record, and a unique platform, Perseo is the partner of choice for the joint development of gut-restricted metabolic therapies. We are currently raising our Series A of CHF 8M, for which we have signed a Term Sheet with a US-based Lead Investor.